Rekvina Laboratories Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	12.65	-	-	-	-
Cost of Revenue	11.82	-	-	-	-
Gross Profit	0.84	-	-	-	-
Selling, General & Admin	2.3	0.45	-	-	-
Other Operating Expenses	1.09	0.93	0.16	0.04	0.75
Operating Expenses	3.39	1.37	0.16	0.04	0.75
Operating Income	-2.55	-1.37	-0.16	-0.04	-0.75
Other Non Operating Income (Expenses)	-	-	-	-0	-0.03
EBT Excluding Unusual Items	-2.55	-1.37	-0.16	-0.05	-0.79
Other Unusual Items	-	-	-	0.04	-
Pretax Income	-2.55	-1.37	-0.16	-0.01	-0.79
Net Income	-2.55	-1.37	-0.16	-0.01	-0.79
Net Income to Common	-2.55	-1.37	-0.16	-0.01	-0.79
Shares Outstanding (Basic)	6	6	6	6	6
Shares Outstanding (Diluted)	6	6	6	6	6
Shares Change (YoY)	0.60%	-	-	-0.66%	-
EPS (Basic)	-0.42	-0.23	-0.03	-0.00	-0.13
EPS (Diluted)	-0.42	-0.23	-0.03	-0.00	-0.13
Gross Margin	6.62%	-	-	-	-
Operating Margin	-20.13%	-	-	-	-
Profit Margin	-20.13%	-	-	-	-
EBIT	-2.55	-1.37	-0.16	-0.04	-0.75
EBIT Margin	-20.13%	-	-	-	-
Revenue as Reported	12.65	-	-	0.04	-
Advertising Expenses	-	0.02	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.